行情

INNT

INNT

INNOVATE BIOPHARMACEUTICALS INC
NASDAQ

实时行情|Nasdaq Last Sale

0.4700
0.0000
0.00%
已收盘, 17:12 04/02 EDT
开盘
0.5000
昨收
0.4700
最高
0.5000
最低
0.4501
成交量
11.33万
成交额
--
52周最高
2.400
52周最低
0.3701
市值
1,942.27万
市盈率(TTM)
-0.5887
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测INNT价格均价为10.00,最高价位10.00,最低价为10.00。

EPS

INNT 新闻

更多
  • 瑞幸“造假门”后:中介机构或连坐 被监管纳入核查
  • 新浪财经 · 1小时前
  • 美股还能大崩盘?估值已近08金融危机!
  • 华盛通 · 2小时前
  • 金融市场腥风血雨 华尔街大行交易业绩表现料出现分化
  • 新浪财经 · 2小时前
  • 刷了十分钟下不了单!探访瑞幸沪上门店:火爆到崩溃
  • 澎湃新闻 · 2小时前

所属板块

生物技术和医学研究
+3.33%
制药与医学研究
+2.79%

热门股票

代码
价格
涨跌幅

INNT 简况

Innovate Biopharmaceuticals, Inc., formerly Monster Digital, Inc., is a clinical stage biotechnology company. The Company is focused on developing novel autoimmune and inflammation therapeutic drugs. Its lead drug candidate, larazotide acetate (INN-202) is a tight junction regulator. Its other products include INN-108 and INN-329 (Secretin). The Company’s INN-108 is a novel small molecule comprised of two active parts with anti- inflammatory and immunodulatory properties coupled through an azo bond. The Company is developing INN-108 as a therapeutic for Ulcerative Colitis (UC). Its Secretin stimulated magnetic resonance cholangiopancreatography (MRCP) is a ionizing, radiation-free assessment of the pancreaticobiliary system. The Company has completed a phase II b clinical trial for celiac disease for INN-202. It is developing INN-108 in a phase II trial for inflammatory bowel disorders, mild to moderate UC and a Gastrointestinal (GI) orphan disease.
展开

微牛提供Innovate Biopharmaceuticals Inc(NASDAQ-INNT)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的INNT股票新闻,以帮助您做出投资决策。